CVM240920C1500
- 0.10
- 0.000.00%
CEL-SCI Newsroom
CEL-SCI's Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to Be in the Treatment Group for Surgery and Radiation
CEL-SCI to Present New Data for Multikine Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age
CEL-SCI Q3 2024 Adj EPS $(0.14) Misses $(0.11) Estimate
Express News | CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
CEL-SCI 3Q Loss/Shr 14c >CVM
Cel-Sci: Fiscal Q3 Earnings Snapshot
CEL-SCI | 10-Q: Q3 2024 Earnings Report
Express News | CEL-SCI Announces Closing of $10.8 Million Offering
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
CEL-SCI Shares Resume Trade
CEL-SCI Shares Halted On Circuit Breaker To The Downside, Stock Now Up 21.9%
CEL-SCI's Offering of 10.8M Shares or Pre-Funded Warrants Prices at $1 a Share >CVM
Express News | CEL-SCI Corp - Offering Price Set at $1.00 per Share
Express News | CEL-SCI Announces Pricing of $10.8 Million Offering
Express News | Amex Halt News Pending Lst 1.475000
CEL-SCI Stock Rallies 40% on Multikine Study Analysis Results
CEL-SCI Shares Are Trading Higher After the Company Announced Results From a Bias Analysis Conducted for Its Concluded Phase 3 Study of Multikine. Multikine Cut the 5-year Risk of Death by Half Compared to Control in Its Target Population.
Express News | CEL-SCI - Data Supports Clinical Effect of Neoadjuvant (Pre-Surgery) Multikine Immunotherapy in Extending Life of Patients in Phase 3 Study
Express News | CEL-SCI Corp - Study Data Are Reliably Interpretable, Statistically Significant